arrow
A

Alessandra Cassano

fondazione policlinico universitario agostino gemelli and irccs
H指数:38
被引数:4,805

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Immunotherapeutic strategies in HPV-positive and HPV-negative recurrent/metastatic oropharyngeal squamous cell carcinoma: from PD-1 blockade to EGFR-directed bispecifics and therapeutic HPV vaccines

人乳头瘤病毒阳性与阴性复发/转移性口咽鳞状细胞癌的免疫治疗策略:从PD-1阻断到EGFR靶向双特异性抗体和治疗性HPV疫苗

2026-05-160
OAAI
Association of a gene-expression subtype to outcome and treatment response in patients with recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab
2024-01-301
OAAI
Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study

卡培他滨辅助治疗新辅助治疗后有残留病灶的三阴性乳腺癌患者: 来自CaRe的真实世界证据,一项多中心观察性研究

2023-05-165
OAAI
Exploratory analysis of the effect of a dexamethasone-sparing regimen for prophylaxis of cisplatin-induced emesis on food intake (LUNG-NEPA study)
2023-01-235
OAAI
Tolerability of Eribulin and correlation between polymorphisms and neuropathy in an unselected population of female patients with metastatic breast cancer: results of the multicenter, single arm, phase IV PAINTER study

未经选择的转移性乳腺癌女性患者人群中Eribulin的耐受性以及多态性与神经病之间的相关性: 多中心,单臂,IV期peter研究的结果

2022-10-282
OAAI
Evaluating the impact of chemotherapy-induced nausea and vomiting on daily functioning in patients receiving dexamethasone-sparing antiemetic regimens with NEPA (netupitant/palonosetron) in the cisplatin setting: results from a randomized phase 3 study
2022-08-2410
OAAI
PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting

Paner研究: 一项来自真实世界环境的HER2-positive晚期乳腺癌患者的多中心观察性研究的20年治疗结果分析

2021-11-296
OAAI
Let-7a-5p, miR-100-5p, miR-101-3p, and miR-199a-3p Hyperexpression as Potential Predictive Biomarkers in Early Breast Cancer Patients
2021-08-2018
OAAI
The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial

ChangeHER试验中转移性乳腺癌HER2-positivity增益的预后相关性

2021-07-026
OAAI
A CT-Based Radiomic Signature Can Be Prognostic for 10-Months Overall Survival in Metastatic Tumors Treated with Nivolumab: An Exploratory Study
2021-05-288
OAAI
Liver Metastasectomy for Metastatic Breast Cancer Patients: A Single Institution Retrospective Analysis
2021-03-087
OAAI
Palbociclib Plus Fulvestrant or Everolimus Plus Exemestane for Pretreated Advanced Breast Cancer with Lobular Histotype in ER+/HER2- Patients: A Propensity Score-Matched Analysis of a Multicenter Retrospective Patient Series

Palbociclib联合氟维司群或依维莫司联合依西美坦治疗ER /HER2患者小叶组织型晚期乳腺癌: 多中心回顾性患者系列的倾向评分匹配分析

2020-12-185
OAAI
Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study

HER2双重阻断治疗HER2阳性晚期乳腺癌的HER2丢失和T-DM1疗效降低: SePHER研究

2020-12-1042
OAAI
The impact of multidisciplinary team management on outcome of hepatic resection in liver-limited colorectal metastases
2020-07-0215
OAAI
The Impact of Locoregional Treatment on Response to Nivolumab in Advanced Platinum Refractory Head and Neck Cancer: The Need Trial

局部区域治疗对晚期铂类难治性头颈癌患者Nivolumab反应的影响: Need试验

2020-04-209
OAAI
Palbociclib-fulvestrant (PALBO-FUL) and everolimus-exemestane (EVE-EXE) for second line hormonal treatment (HT) of metastatic breast cancer (MBC) with lobular histology: A propensity score matched analysis

Palbociclib-氟维司坦 (palbo-ful) 和依维莫司-依西美坦 (EVE-EXE) 用于小叶组织学转移性乳腺癌 (MBC) 的二线激素治疗 (HT): 倾向评分匹配分析

2020-02-150
PRE